Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway

  • Authors:
    • Weiping Zhu
    • Dihua Zhan
    • Lu Wang
    • Dening Ma
    • Mingrong Cheng
    • Huipeng Wang
    • Jiaying Zhao
    • Yuankun Cai
    • Zhijian Cheng
  • View Affiliations

  • Published online on: May 27, 2016     https://doi.org/10.3892/or.2016.4839
  • Pages: 845-852
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

TRAIL is a tumor-selective apoptosis-inducing cytokine playing a vital role in the surveillance and elimination of some tumor cells. However, some tumors are resistant to TRAIL treatment. Proteasome inhibitor MG132 exhibits anti-proliferative and pro-apoptotic properties in many tumors. In this study, we demonstrated that proteasome inhibitor MG132 in vitro and in vivo potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells. MG132 was able to inhibit the proliferation of GBC-SD cells and induce apoptosis in a dose-dependent manner. The induction of apoptosis by proteasome inhibitor MG132 was mainly through the extrinsic apoptotic pathways of caspase activation such as caspase-8, caspase-3 and PARP cleavage. In addition, this process was also dependent on the upregulation of death receptor 5 (DR5), which promoted TRAIL-induced apoptosis in GBC-SD cells. Taken together, these findings indicate that MG132 possesses anti-gallbladder cancer potential that correlate with regulation of DR5-dependent pathway, and suggest that MG132 may be a promising agent for sensitizing GBC-SD cells to TRAIL-induced apoptosis.
View Figures
View References

Related Articles

Journal Cover

August-2016
Volume 36 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu W, Zhan D, Wang L, Ma D, Cheng M, Wang H, Zhao J, Cai Y and Cheng Z: Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway. Oncol Rep 36: 845-852, 2016.
APA
Zhu, W., Zhan, D., Wang, L., Ma, D., Cheng, M., Wang, H. ... Cheng, Z. (2016). Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway. Oncology Reports, 36, 845-852. https://doi.org/10.3892/or.2016.4839
MLA
Zhu, W., Zhan, D., Wang, L., Ma, D., Cheng, M., Wang, H., Zhao, J., Cai, Y., Cheng, Z."Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway". Oncology Reports 36.2 (2016): 845-852.
Chicago
Zhu, W., Zhan, D., Wang, L., Ma, D., Cheng, M., Wang, H., Zhao, J., Cai, Y., Cheng, Z."Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway". Oncology Reports 36, no. 2 (2016): 845-852. https://doi.org/10.3892/or.2016.4839